{"id":"placebo-for-ribavirin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1643","moleculeType":"Small molecule","molecularWeight":"244.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect, natural disease progression, or regression to the mean rather than direct drug action. Placebos are essential for blinded trial design to isolate the true therapeutic benefit of the investigational agent.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:24.323Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial for Ribavirin (antiviral indication, likely viral hepatitis or respiratory viral infection)"}]},"trialDetails":[{"nctId":"NCT01353911","phase":"PHASE2","title":"Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":368},{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT01849562","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2013-04","conditions":"Hepatitis C, Chronic","enrollment":30},{"nctId":"NCT04605588","phase":"PHASE2","title":"A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-12-02","conditions":"SARS-CoV Infection, Covid19","enrollment":7},{"nctId":"NCT01715415","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Chronic Hepatitis C Infection","enrollment":395},{"nctId":"NCT01716585","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Chronic Hepatitis C Infection","enrollment":636},{"nctId":"NCT01767116","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":"Chronic Hepatitis C Infection","enrollment":419},{"nctId":"NCT01833533","phase":"PHASE3","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03","conditions":"Chronic Hepatitis C Infection","enrollment":305},{"nctId":"NCT04838145","phase":"PHASE2","title":"The Diabetes Virus Detection and Intervention Trial","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2018-08-30","conditions":"Type1 Diabetes Mellitus, Enterovirus","enrollment":96},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT01717326","phase":"PHASE2","title":"A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-07","conditions":"Hepatitis C","enrollment":573},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT00166296","phase":"PHASE2","title":"Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-03","conditions":"Major Depressive Disorder, Hepatitis C, Chronic","enrollment":133},{"nctId":"NCT02293941","phase":"PHASE2","title":"Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies","status":"TERMINATED","sponsor":"TaiwanJ Pharmaceuticals Co., Ltd","startDate":"2014-05","conditions":"Chronic Hepatitis C","enrollment":54},{"nctId":"NCT00823862","phase":"PHASE1","title":"Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2008-10","conditions":"Chronic Hepatitis C","enrollment":34},{"nctId":"NCT00990938","phase":"PHASE1","title":"Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients","status":"COMPLETED","sponsor":"Idera Pharmaceuticals, Inc.","startDate":"2009-09","conditions":"Hepatitis C, Treatment Naïve, Genotype 1 Patients","enrollment":63},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT01965535","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10","conditions":"HCV Infection","enrollment":155},{"nctId":"NCT00100659","phase":"PHASE3","title":"PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-12","conditions":"Chronic Hepatitis C","enrollment":114},{"nctId":"NCT01370642","phase":"PHASE3","title":"Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":294},{"nctId":"NCT00880763","phase":"PHASE2","title":"A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-20","conditions":"Hepatitis C","enrollment":90},{"nctId":"NCT00704184","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07-25","conditions":"Hepatitis C","enrollment":95},{"nctId":"NCT00704405","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03-27","conditions":"Hepatitis C, Chronic","enrollment":285},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT00793793","phase":"PHASE1","title":"Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"Hepatitis C, Chronic","enrollment":96},{"nctId":"NCT01314261","phase":"PHASE2","title":"Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-03","conditions":"Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection","enrollment":37},{"nctId":"NCT00851890","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-03","conditions":"Chronic Hepatitis C Virus Infection","enrollment":30},{"nctId":"NCT01355289","phase":"PHASE2","title":"Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-11","conditions":"Thrombocytopenia","enrollment":65},{"nctId":"NCT01265511","phase":"PHASE2","title":"Study of SCY-635, Pegasys and Copegus in Hepatitis C","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2010-11","conditions":"Hepatitis C Infection","enrollment":10},{"nctId":"NCT00317746","phase":"PHASE3","title":"Trial of Citalopram for the Prevention of Depression","status":"COMPLETED","sponsor":"Marina Klein","startDate":"2006-11","conditions":"Depression, HIV Infections, Hepatitis C","enrollment":76},{"nctId":"NCT01890200","phase":"PHASE3","title":"The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)","status":"WITHDRAWN","sponsor":"TCM Biotech International Corp.","startDate":"2015-06","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT01482390","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-30","conditions":"Hepatitis C","enrollment":80},{"nctId":"NCT01153919","phase":"PHASE2","title":"Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2010-06-30","conditions":"Hepatitis C Infection, Thrombocytopenia","enrollment":27},{"nctId":"NCT00959699","phase":"PHASE2","title":"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"HIV Infections, Hepatitis C, HCV Infection","enrollment":99},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00845065","phase":"PHASE3","title":"Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02","conditions":"Hepatitis C, Chronic","enrollment":202},{"nctId":"NCT00705432","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":1472},{"nctId":"NCT00978497","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-09","conditions":"HCV Infection","enrollment":97},{"nctId":"NCT01470651","phase":"PHASE4","title":"Armodafinil for Patients Starting Hepatitis C Virus Treatment","status":"TERMINATED","sponsor":"Research Foundation for Mental Hygiene, Inc.","startDate":"2011-10","conditions":"Hepatitis C","enrollment":26},{"nctId":"NCT01278134","phase":"PHASE2","title":"A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":170},{"nctId":"NCT00963885","phase":"PHASE2","title":"A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Hepatitis C, Chronic","enrollment":229},{"nctId":"NCT01318694","phase":"PHASE3","title":"Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2011-03","conditions":"Hepatitis C","enrollment":1081},{"nctId":"NCT01358864","phase":"PHASE3","title":"Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-06","conditions":"Hepatitis C, Chronic","enrollment":678},{"nctId":"NCT01183169","phase":"PHASE2","title":"Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2010-08","conditions":"Hepatitis C","enrollment":459},{"nctId":"NCT02716779","phase":"PHASE2","title":"Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-04","conditions":"Hepatitis C, Chronic","enrollment":68},{"nctId":"NCT00807001","phase":"PHASE1, PHASE2","title":"Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12","conditions":"Chronic Hepatitis C (HCV)","enrollment":41},{"nctId":"NCT01482403","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":58},{"nctId":"NCT01445795","phase":"PHASE1, PHASE2","title":"Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-09","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT01485991","phase":"PHASE3","title":"TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-02","conditions":"Hepatitis C","enrollment":771},{"nctId":"NCT00905632","phase":"PHASE1","title":"4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-05","conditions":"Hepatitis C, Chronic","enrollment":75},{"nctId":"NCT00077649","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Hepatitis C, Chronic","enrollment":188},{"nctId":"NCT01323244","phase":"PHASE3","title":"A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-12","conditions":"Hepatitis C","enrollment":142},{"nctId":"NCT00854802","phase":"NA","title":"A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2009-01","conditions":"Chronic Hepatitis C","enrollment":290},{"nctId":"NCT01728324","phase":"PHASE3","title":"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-11","conditions":"Hepatitis C, Chronic","enrollment":496},{"nctId":"NCT01257204","phase":"PHASE2","title":"Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12","conditions":"Hepatitis C Virus","enrollment":196},{"nctId":"NCT00774397","phase":"PHASE2","title":"Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-10","conditions":"Hepatitis C, Chronic","enrollment":719},{"nctId":"NCT00895882","phase":"PHASE2","title":"Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11","conditions":"Chronic Genotype 1 Hepatitis C Virus Infection","enrollment":""},{"nctId":"NCT01170962","phase":"PHASE2","title":"Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":512},{"nctId":"NCT01448044","phase":"PHASE3","title":"Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C","enrollment":152},{"nctId":"NCT01309932","phase":"PHASE2","title":"Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"Hepatitis C","enrollment":165},{"nctId":"NCT01973049","phase":"PHASE3","title":"UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-12","conditions":"Hepatitis C","enrollment":202},{"nctId":"NCT01343888","phase":"PHASE3","title":"Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-04","conditions":"Hepatitis C","enrollment":656},{"nctId":"NCT01297270","phase":"PHASE3","title":"Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-04","conditions":"Hepatitis C","enrollment":658},{"nctId":"NCT01725529","phase":"PHASE3","title":"An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-11","conditions":"Hepatitis C, Chronic","enrollment":457},{"nctId":"NCT00947349","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-07","conditions":"Hepatitis C, Pharmacokinetics","enrollment":22},{"nctId":"NCT01852604","phase":"PHASE2","title":"Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-03","conditions":"Chronic Hepatitis C Virus","enrollment":143},{"nctId":"NCT00560690","phase":"PHASE4","title":"The Effect of Adding Metformin to the Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2007-12","conditions":"Hepatitis C","enrollment":140},{"nctId":"NCT01371604","phase":"PHASE2","title":"Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":68},{"nctId":"NCT01074008","phase":"PHASE2","title":"A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":"Hepatitis C, HCV, Chronic Hepatitis C Infection","enrollment":74},{"nctId":"NCT01682720","phase":"PHASE3","title":"Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-09","conditions":"Hepatitis C","enrollment":421},{"nctId":"NCT01197157","phase":"PHASE2, PHASE3","title":"Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients","status":"COMPLETED","sponsor":"National Liver Institute, Egypt","startDate":"2010-09","conditions":"Hepatitis C","enrollment":200},{"nctId":"NCT00627926","phase":"PHASE3","title":"A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2008-03","conditions":"Hepatitis C","enrollment":1095},{"nctId":"NCT00556504","phase":"PHASE2","title":"The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection","status":"COMPLETED","sponsor":"TCM Biotech International Corp.","startDate":"2007-07","conditions":"Chronic Hepatitis C","enrollment":84},{"nctId":"NCT00420784","phase":"PHASE2","title":"A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-02","conditions":"Hepatitis C","enrollment":465},{"nctId":"NCT00372385","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-08","conditions":"Chronic Hepatitis C","enrollment":334},{"nctId":"NCT00336479","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-06","conditions":"Chronic Hepatitis C","enrollment":263},{"nctId":"NCT00882908","phase":"PHASE2","title":"A Study of TMC435 in Combination With Pegylated Interferon Alp\\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-06","conditions":"Hepatitis C","enrollment":386},{"nctId":"NCT01290679","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-03","conditions":"Hepatitis C","enrollment":393},{"nctId":"NCT00980330","phase":"PHASE2","title":"A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-10","conditions":"Hepatitis C","enrollment":463},{"nctId":"NCT01289782","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":395},{"nctId":"NCT01604850","phase":"PHASE3","title":"Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-06","conditions":"Chronic Hepatitis C","enrollment":202},{"nctId":"NCT00561353","phase":"PHASE2","title":"A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT01542788","phase":"PHASE3","title":"Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Chronic Hepatitis C","enrollment":278},{"nctId":"NCT01629732","phase":"PHASE2","title":"Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2013-03","conditions":"Hepatitis C Virus","enrollment":""},{"nctId":"NCT00495391","phase":"PHASE2","title":"Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2007-07","conditions":"Chronic Hepatitis C","enrollment":64},{"nctId":"NCT01281839","phase":"PHASE3","title":"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-02","conditions":"Hepatitis C","enrollment":394},{"nctId":"NCT01188772","phase":"PHASE2","title":"Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":147},{"nctId":"NCT01054729","phase":"PHASE2","title":"Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-01","conditions":"Hepatitis C","enrollment":64},{"nctId":"NCT00911963","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2009-04","conditions":"Hepatitis C","enrollment":49},{"nctId":"NCT01371578","phase":"PHASE2","title":"Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":163},{"nctId":"NCT00637923","phase":"PHASE2","title":"Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2008-03","conditions":"Chronic Hepatitis C","enrollment":112},{"nctId":"NCT01435044","phase":"PHASE2","title":"Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":239},{"nctId":"NCT01271790","phase":"PHASE2","title":"A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-10","conditions":"Hepatitis C, Chronic","enrollment":245},{"nctId":"NCT01356160","phase":"PHASE2","title":"GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":351},{"nctId":"NCT01225380","phase":"PHASE2","title":"A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-10","conditions":"Chronic Hepatitis C Infection","enrollment":324},{"nctId":"NCT00703118","phase":"PHASE3","title":"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-10","conditions":"Hepatitis C, Chronic","enrollment":663},{"nctId":"NCT01292239","phase":"PHASE3","title":"A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":183},{"nctId":"NCT01434498","phase":"PHASE2","title":"GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-09","conditions":"Chronic Genotype 1a or 1b HCV Infection","enrollment":163},{"nctId":"NCT01435226","phase":"PHASE2","title":"GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":422,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Ribavirin","genericName":"Placebo for Ribavirin","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trial for Ribavirin (antiviral indication, likely viral hepatitis or respiratory viral infection).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}